Venus Remedies Ltd (VENUSREM)
NSE · Healthcare · Pharmaceuticals & Biotechnology · Pharmaceuticals
₹1,238.60
As of 30 Oct 2026 close.
Facts from reported results and exchange filings. Not investment advice.
Share price
Prices load here as you scroll to them.
Last close ₹1,238.60 on 30 Oct 2026. The share price traded between ₹432.10 and ₹2,044.30 (intraday) over the last 12 months.
The closes as a table
| Date | Close |
|---|
Key figures
1-year range (intraday)
Low ₹432.10High ₹2,044.30
Exchange surveillance
LT-ASM 4 Long-term ASM (Additional Surveillance Measure), Stage 4
The exchange's long-term Additional Surveillance Measure list: stocks it watches more closely after unusual price moves or trading over weeks or months. Stage 4: 100% margin, a 5% price band, and trade-to-trade settlement. List as of 30 Oct 2026. From the exchange's published surveillance lists: a measure the exchange applies for a time. It is a fact about trading rules, not a view on the company.
T2T Trade-to-trade settlement
The stock trades in the trade-to-trade segment (BE or BZ series): every trade is settled by delivery of the shares, so a position can't be opened and closed within the same day. List as of 30 Oct 2026. From the exchange's published surveillance lists: a measure the exchange applies for a time. It is a fact about trading rules, not a view on the company.
Price trend
- Stage 3 (topping): the 150-day average has stopped rising, or the price is below a rising one, for 4 trading days.
- Supertrend (10, 3): the price has closed below the line for 8 trading days.
Revenue and profit
| Year | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue | 597 | 552 | 596 | 645 | 766 |
| Net profit | 41 | 27 | 28 | 45 | 103 |
| EBITDA margin | 10% | 11% | 10% | 11% | 19% |
| Borrowings | 43 | 42 | 41 | 2 | 12 |
₹ crore. Over three years, compounded: revenue grew 11.5% a year, net profit grew 56.3% a year.
Recent filings
- 26 Oct 2026
Financial results: Outcome of Board Meeting - 16 Oct 2026
'Venus Remedies Secures Five Marketing Authorisations Across Four Key International Markets' - 14 Oct 2026
'Social Media Communication regarding special window for re-lodgement of transfer requests' - 30 Sep 2026
'Intimation regarding change in Corporate Identification Number (CIN).' - 7 Sep 2026
Social Media Post on awareness on transfer of physical shares '' - 21 Aug 2026
Financial results: Shareholders meeting
Questions about Venus Remedies Ltd
What is Venus Remedies Ltd's market value?
Venus Remedies Ltd's market value is ₹1,610 crore as of 30 Oct 2026 close: the last close times the shares in issue. Its P/E is 13.6, the last close over earnings per share for the last four reported quarters.
Who are Venus Remedies Ltd's largest named shareholders?
In the shareholding pattern for the quarter ended 30 Sep 2026, the largest named holders above 1% were: Sunev Pharma Solutions Pvt Ltd (promoter group) 17.21%; PAWAN CHAUDHARY (promoter group) 12.82%; MANU CHAUDHARY (promoter group) 11.73%. Percentages are of all shares.
Go further with VENUSREM
Free to start: test a trading idea on VENUSREM's real prices after costs, or open the full deep dive with ten years of numbers, red flags and management's record.
Same industry
The largest companies in the same industry (Pharmaceuticals), by market value.
Browse companies
The companies before and after this one, A to Z, and the lists it is in.
How these figures are worked out
The net profit for the last 12 months is the four latest reported quarters, so it can differ from the newest year's in the table below.
- Last close: the closing price on the date shown. The page follows the market's close; it doesn't show prices during the session. A price older than the market's latest close, or a last trade that isn't a close, is labelled as the last price, with the session it is from.
- 1-year range: the lowest and highest prices traded during the sessions of the last year (intraday), so they can lie outside the closing prices.
- Market cap: the last close times the shares in issue. It is n/a when it doesn't agree with the company's own reported figures (for example a depositary share counted as an ordinary share).
- P/E: the last close divided by earnings per share over the last four reported quarters, the profit that belongs to the company's shareholders per share, as the company reports it. So P/E can differ from market cap divided by the net profit shown (a different share count, or the profit before minority interests; where they differ by more than 10%, a note under the figures gives both). A company that reports only once a year has its latest year's earnings, and the P/E names that year; when that year ended more than about 15 months before the close, P/E is n/a. A loss has no P/E. Above 1,000 it is n/a.
- EBITDA margin: operating profit before depreciation, interest and tax (and before other income), as a share of revenue in the latest reported year, the table's last column. The results give it in whole percent.
- Net margin: net profit as a share of revenue in the latest reported period. Return on equity, the margins and debt to equity each use inputs from that one year; if one input is missing for it, the figure is n/a. When that year ended more than about 15 months before the close, they are n/a too.
- Dividend yield: every dividend per share with an ex-date in the 12 months to the last close, special dividends included, as a share of that close. n/a when the company's dividends couldn't be read.
- n/m: not meaningful. A margin or return beyond ±1,000% comes from revenue or equity near zero, so it is not shown as a number.